[Skip to Content]

Upstate Active Clinical Trials

Study Title:

ACNS1831 - A Phase 3 Study of Selumetinib (IND #77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

What is the purpose of the study? (in Layman's terms, please describe the study)

Treatment

Upstate Institutional Review Board (IRB) Number:

1988697

Study/Protocol ID:

ACNS1831

Study Phase:

3

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

≥ 2 years and ≤ 21 years with newly diagnosed or have previously diagnosed NF-1associated LGG that has not been treated with any modality other than surgery.

What is involved if I participate?

  • How long is the study?
    until accrual is met
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    labs, eye assessments, imaging, neurocognitive testing

Where will the study take place?

University Hospital Pediatric Hematology/Oncology inpatient and outpatient units.

Other Information:

None

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top